Glass House BrandsGLAS 44 EV-to-EBIT is -73.30 as of Jul. 01, 2026. GuruFocus rates GLAS with a GF Score™ of 44/100 and a GF Value™ of $6.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, Glass House Brands ranks worse than 145137.74% on this metric.
Glass House Brands (NYSE:GLAS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Glass House Brands's Enterprise Value for the quarter that ended in Mar. 2026 was $855.8 Mil.
Glass House Brands's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glass House Brands EV-to-EBIT Related Terms
Glass House Brands EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Glass House Brands's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Glass House Brands's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glass House Brands EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glass House Brands's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Glass House Brands's EV-to-EBIT falls into.
Glass House Brands's current Enterprise Value is $1,220.2 Mil.
Glass House Brands's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glass House Brands (GLAS) has a EV-to-EBIT of -73.30 as of Jul. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Glass House Brands and its competitors. According to the industry distribution chart, Glass House Brands ranks #999999 out of 689 companies in the Drug Manufacturers industry.
Is Glass House Brands' EV-to-EBIT too high?
Glass House Brands' current EV-to-EBIT is -73.30. Based on the distribution chart, Glass House Brands ranks #999999 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Glass House Brands has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glass House Brands' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glass House Brands ranks #999999 out of 689 companies for EV-to-EBIT. This places Glass House Brands in the lower half of its industry. The industry median EV-to-EBIT is 15.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.80, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Glass House Brands and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glass House Brands's current EV-to-EBIT is -73.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glass House Brands stock overvalued right now?
Based on GuruFocus' analysis, Glass House Brands (GLAS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.46, compared to a current price of $13.00 — trading 101.2% above its estimated fair value. The current EV-to-EBIT is -73.30. Glass House Brands' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Glass House Brands (GLAS), the current EV-to-EBIT is -73.30 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glass House Brands (GLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Glass House Brands stock appears to be overvalued.
The current stock price of $13.00 is trading 101.2% above its estimated GF Value™ of $6.46.
GuruFocus considers Glass House Brands to be Significantly Overvalued.
Key valuation signals for GLAS:
EV-to-EBIT: -73.30
GF Value™: $6.46 vs. price of $13.00 (101.2% above fair value)
No single metric tells the full story. See the GLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
44GF Score
Get the complete analysis for GLAS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAS has been successfully added to your 
